Podcasts about reachmd

Host: Steve Jackson, PharmD Guest: Nisha Joseph, MD This is a non-certified educational series produced and controlled by ReachMD. As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta.

Host: Priya Vakharia, MD Guest: Andrew Moshfeghi, MD The SOL-1 Phase 3 superiority trial compared the efficacy and safety of the investigational product OTX-TKI (axitinib intravitreal hydrogel) with aflibercept 2 mg. The primary endpoint was proportion of subjects who maintained visual acuity, defined as

Guest: Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.

CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It's not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice.For more information please visit the Heart Failure Congress 2026 website.=

Guest: John W. Ostrominski, MD, MPH Despite advances in glycemic management, blood pressure control, lipid lowering, and disease-modifying therapies, patients with chronic kidney disease (CKD) and type 2 diabetes continue to face substantial residual cardiovascular risk. In this program, Dr. John Ostrominski reviews emerging evidence linking low-grade systemic inflammation to adverse cardiovascular outcomes in this high-risk population, highlighting findings from the FIDELITY pooled analysis of FIDELIO-DKD and FIGARO-DKD. Dr. Ostrominski is a fellow specializing in cardiovascular disease and obesity medicine at Brigham and Women's Hospital and Harvard Medical School. He spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Guest: Kimberly Narain, MD, MPH, PhD Cost-related medication nonadherence remains a significant but often hidden barrier to effective diabetes care, with out-of-pocket costs preventing patients from accessing essential therapies. Dr. Kimberly Narain joins us to explain why clinicians should look beyond insurance status alone and consider affordability challenges when developing strategies to improve diabetes outcomes. Dr. Narain is an Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, as well as the Director of Health Services and Health Optimization Research at the Iris Cantor UCLA Women's Health Center. She also spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Host: Steve Jackson, PharmD Guest: Souptik Barua, PhD Guest: Emily Johnston, MPH, PhD Can older adults successfully engage with telehealth, wearable technology, and digital health tools to prevent type 2 diabetes? In this conversation with Dr. Steve Jackson, Ds. Emily Johnston and Dr. Souptik Barua discuss emerging insights on how these strategies could improve accessibility and engagement in a high-risk population. Dr. Johnston is a Research Assistant Professor in the Department of Medicine, and Dr. Barua is an Assistant Professor in the Division of Precision Medicine at the NYU Grossman School of Medicine. They presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Javier Morales, MD, FACP, FACE For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Guest: Javier Morales, MD, FACP, FACE From proactive screening to once-weekly insulin, the treatment landscape for type 1 diabetes is evolving rapidly. Join Dr. Javier Morales to hear about current and emerging care strategies in these patients, a topic he also discussed at the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Guest: Elizabeth S. Gromisch, PhD Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch explores both traditional and digital cognitive screening tools for MS and shares real-world insights on selecting and implementing assessments across a range of clinical settings. Dr. Gromisch is a research neuropsychologist at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research at Mount Sinai Rehabilitation Hospital, Trinity Health of New England. She also discussed this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Elizabeth S. Gromisch, PhD Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch explores both traditional and digital cognitive screening tools for MS and shares real-world insights on selecting and implementing assessments across a range of clinical settings. Dr. Gromisch is a research neuropsychologist at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research at Mount Sinai Rehabilitation Hospital, Trinity Health of New England. She also discussed this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Ibrahim Hussain, M.D. Neurological spine surgeon Dr. Ibrahim Hussain explains how expandable cages are being used in minimally invasive transforaminal lumbar interbody fusions to optimize patient outcomes. These cages can be inserted with a very low profile to restore height and lordosis, and enable a faster recovery. At Och Spine at NewYork-Presbyterian, surgeons are pursuing innovative solutions to provide a better quality of life for patients with degenerative disc disease and other spine conditions. © 2026 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

Host: Steve Jackson, PharmD Guest: Matthew J. Matasar, MD Guest: Tycel Phillips, MD This is a non-certified educational series produced and controlled by ReachMD. Timely referral for CAR T-cell therapy remains a critical challenge for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). From communication gaps between providers to logistical challenges and delays, barriers throughout the treatment pathway can limit timely access to care. Tune in to learn about evolving strategies that can help us streamline coordination and expand access to CAR T-cell therapy as Dr. Steve Jackson speaks with Dr. Matthew Matasar and Dr. Tycel Phillips. Dr. Matasar is the Chief of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Phillips is an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Guest: Mirella Mourad, M.D. On this episode of Advances in Care, host Erin Welsh is joined by Dr. Mirella Mourad, maternal-fetal medicine specialist at NewYork-Presbyterian and co-director of the Preterm Birth Prevention Center at Columbia, to explore a groundbreaking new technology aimed at improving the diagnosis and treatment of preterm birth. Preterm birth impacts approximately 1 in 10 pregnancies in the United States, making it a leading cause of neonatal complications and long-term health challenges. But despite its prevalence and associated risks, innovative solutions to address the condition have lagged behind. To address this gap, Dr. Mourad and her collaborator, Dr. Kristin Meyers, a professor of mechanical engineering at Columbia's School of Engineering, are developing a new tool: a patient-specific “digital twin” of the cervix. This advanced technology has the potential to revolutionize obstetric care for patients by allowing clinicians to test new treatment methods, collect data to better understand why certain people are at risk for preterm birth, and overall, catalyze innovation in the historically under-researched field of maternal-fetal medicine, ultimately helping to drive better outcomes and successful pregnancies. Dr. Mourad also discusses how this digital twin can potentially assist with identifying women with placenta accreta spectrum disorder and inform more precise and …

CME credits: 0.50 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/ Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about how we can best partner with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-biology-environmental-and-lifestyle-influences-in-ibd/56891/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-microbiomes-role-in-ibd-management/56892/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-challenges-addressed/56894/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-of-ibd-the-war-within/56889/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-inflammation-in-ibd-localized-vs-systemic-strategies/56890/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/genetic-susceptibility-in-ibd-from-risk-genes-to-clinical-impact/56893/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 0.25 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-upated-kdigo-clinical-practice-guideline-recommndations-to-maximize-proteinuria-reduction-in-patients-with-igan/26630/ Our experts review updated KDIGO practice guideline recommendations for proteinuria reduction in IgA nephropathy (IgAN) and their implications for clinical care. Drs. Chee Kay Cheung and Claudia Seikrit examine the shift toward lower proteinuria targets (

CME credits: 0.25 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/ There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourinary Oncology and the Phase I Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-loop-structured-follow-up-and-patient-communication/56708/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/unseen-impact-of-nps-in-ad-domains-and-burden/56764/ This series of brief episodes examines Alzheimer's disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer's disease, as well as novel treatments for agitation and related NPS. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/tau-therapies-and-clinical-translation-mechanistic-approaches/56762/ This series of brief episodes examines Alzheimer's disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer's disease, as well as novel treatments for agitation and related NPS. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Amyloid-Therapies-in-Practice-Not-All-Are-Created-Equal/56761/ This series of brief episodes examines Alzheimer's disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer's disease, as well as novel treatments for agitation and related NPS. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Catching-Demodex-in-the-Act/56703/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/At-the-Intersection-of-DB-DED-MGD-and-Other-Forms-of-Blepharitis/56704/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/nps-agitation-evidence-and-emerging-mechanisms-of-management/56766/ This series of brief episodes examines Alzheimer's disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer's disease, as well as novel treatments for agitation and related NPS. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/nps-psychosis-circuits-treatment-and-new-hope/56765/ This series of brief episodes examines Alzheimer's disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer's disease, as well as novel treatments for agitation and related NPS. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.25 Valid until: 24-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/ This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden of this disease, challenges in diagnosis, and the importance of recognizing symptoms that are often underestimated. The program reviews current evidence-based and targeted treatment strategies to support personalized care across clinical settings. Faculty also goes in-depth on shared decision-making and integrating patient perspectives into management plans. Multidisciplinary approaches to monitoring treatment response, managing adverse events, and sustaining quality of life are also highlighted.=

CME credits: 1.00 Valid until: 23-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/ This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical trial data, adverse event management, and practical applications through real-world case discussions. The activity emphasizes evidence-based sequencing, MRD assessment, and safety monitoring to support optimal patient outcomes.=

CME credits: 1.00 Valid until: 20-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/ Glaucoma care is shifting from a narrow focus on pressure targets to a broader, patient-centered approach that balances durable intraocular pressure (IOP) control with preservation of the ocular surface, comfort, and real-world adherence. But, daily practice often still defaults to drop-heavy regimens that can erode the very ocular surface on which long-term success depends. The chronic use of preserved topical medications can compromise the cornea and conjunctiva, perpetuating ocular surface disease (OSD) and ocular surface inflammation (OSI). These conditions not only degrade comfort and quality of life but also undermine adherence, accelerate treatment failure, and reduce the success rates of both medical and surgical interventions. Recent expert consensus underscores that every glaucoma patient should be screened for OSD/OSI, yet implementation remains inconsistent in daily practice. Contemporary perspectives and data support a shift toward ocular surface-sparing strategies, including preservative-free options, earlier laser strategies, and newer tear-restorative, anti-inflammatory, and neuromodulatory therapeutic options when OSD does occur.=

CME credits: 1.00 Valid until: 20-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54091/ Neurotrophic keratitis (NK) remains significantly underdiagnosed because early findings are easily mistaken for dry eye disease and other ocular surface disorders. Although reduced corneal sensitivity is the defining feature of NK, corneal sensitivity testing is not routinely performed, resulting in missed opportunities to identify stage 1 NK when intervention is most effective. Treatment at stage 1 can preserve corneal sensitivity and prevent progression to epithelial defects, but many clinicians may lack the confidence needed to initiate treatment earlier. This activity has been designed to improve clinicians' ability to differentiate and diagnose NK and to select optimal treatment regimens based on evidence from recent studies and current guidelines.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.